摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl] amino }pyridin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

中文名称
——
中文别名
——
英文名称
N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl] amino }pyridin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
英文别名
N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-{2,5-Difluoro-4-[(2-{([3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;1-N'-[2,5-difluoro-4-[2-[(3-hydroxyazetidine-1-carbonyl)amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl] amino }pyridin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide化学式
CAS
——
化学式
C26H22F3N5O5
mdl
——
分子量
541.486
InChiKey
QPVJKVZJKIBVSI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    39
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    133
  • 氢给体数:
    4
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Process for preparing phenoxypyridine derivatives
    申请人:Nagai Mitsuo
    公开号:US20080214815A1
    公开(公告)日:2008-09-04
    A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R 1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R 2 , R 3 , R 4 and R 5 may be the same or different and each represents hydrogen or fluorine; and R 6 represents hydrogen or fluorine.
    制备一种由化学式(I)表示的化合物的方法: 包括将由化学式(II)表示的化合物或其盐: 与由化学式(III)表示的化合物: 在缩合试剂的存在下反应, 其中R 1 代表1)可选择地取代的氮杂环丙烷-1-基,2)可选择地取代的吡咯烷-1-基,3)可选择地取代的哌啶-1-基等;R 2 ,R 3 ,R 4 和R 5 可以相同也可以不同,每个代表氢或氟;而R 6 代表氢或氟。
  • PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME
    申请人:MATSUSHIMA Tomohiro
    公开号:US20080318924A1
    公开(公告)日:2008-12-25
    The invention provides acid addition salts of the compounds represented by formula (1) or (2), or crystals thereof, and processes for preparing the same. The salts or crystals have HGFR inhibitory activity and excellent physical properties (solubility, safety, etc.) and are therefore useful as anti-tumor agents, angiogenesis inhibitors and inhibitors for metastasis for a various types of tumor.
    本发明提供了由公式(1)或(2)所代表的化合物的酸加成盐或其晶体,并提供了制备它们的方法。这些盐或晶体具有HGFR抑制活性和优异的物理性质(溶解度、安全性等),因此可用作多种类型肿瘤的抗肿瘤剂、抑制血管生成的抑制剂以及抑制转移的抑制剂。
  • Novel pyridine derivatives and pyrimidine derivatives (3)
    申请人:Matsushima Tomohiro
    公开号:US20080319188A1
    公开(公告)日:2008-12-25
    A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]
    以下化合物,其盐或水合物,具有优异的肝细胞生长因子受体(HGFR)抑制活性,表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。[其中,R1代表3-至10-成员的非芳香族杂环基团等;R2和R3代表氢;R4、R5、R6和R7可以相同或不同,每个代表氢、卤素、C1-6烷基或类似物;R8代表氢或类似物;R9代表3-至10-成员的非芳香族杂环基团等;n代表1或2的整数;X代表-CH═,氮或类似物。]
  • NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3)
    申请人:MATSUSHIMA Tomohiro
    公开号:US20100075944A1
    公开(公告)日:2010-03-25
    A compound represented by the following formula, or a salt thereof or a hydrate of the foregoing, has excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity, and cancer metastasis inhibitory activity. R 1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.
    以下化合物的分子式,或其盐或水合物,具有出色的肝细胞生长因子受体(HGFR)抑制活性,并表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。其中,R1代表3-10个成员的非芳香杂环基团等;R2和R3代表氢;R4、R5、R6和R7可以相同也可以不同,每个代表氢、卤素、C1-6烷基或类似物;R8代表氢或类似物;R9代表3-10个成员的非芳香杂环基团等;n代表1或2的整数;X代表-CH═、氮或类似物。
  • Pyridine derivatives and pyrimidine derivatives (3)
    申请人:Eisai R&D Management Co., Ltd.
    公开号:US07855290B2
    公开(公告)日:2010-12-21
    A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]
    以下化合物的公式,其盐或其水合物具有出色的肝细胞生长因子受体(HGFR)抑制活性,并表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。[R1代表3-至10-成员非芳香杂环基团或类似物;R2和R3代表氢;R4、R5、R6和R7可以相同也可以不同,每个代表氢、卤素、C1-6烷基或类似物;R8代表氢或类似物;R9代表3-至10-成员非芳香杂环基团或类似物;n表示1或2;X表示-CH═、氮或类似物。]
查看更多